Pleural effusion and molecular response in dasatinib-treated chronic myeloid leukemia patients in a real-life Italian multicenter seriesAlessandra Iurlo, Michele Baccarani, Sara Galimberti et al.|Annals of Hematology|2017Cited by 38
Imatinib and polypharmacy in very old patients with chronic myeloid leukemia: effects on response rate, toxicity and outcomeAlessandra Iurlo, Pier Mannuccio Mannucci, Alessandro Nobili et al.|Oncotarget|2016Cited by 35
The <i>hOCT1</i> and <i>ABCB1</i> polymorphisms do not influence the pharmacodynamics of nilotinib in chronic myeloid leukemiaSara Galimberti, Antonello Di Paolo, Cristina Bucelli et al.|Oncotarget|2017Cited by 13
Complete Reversion of Imatinib-Induced Hepatotoxicity in Chronic Myeloid Leukemia Patients by Low-Intermediate Dose Corticosteroid.Dario Ferrero, Mario Boccadoro, Enrico Maria Pogliani et al.|Blood|2005Cited by 8
EFFICACY AND SAFETY PROFILE OF DASATINIB IN A SUBSET OF VERY ELDERLY PATIENS WITH CHRONIC MYELOID LEUKEMIA (CML) RESISTANT/INTOLERANT TO IMATINIBFrancesco Cavazzini, G Gozzini, Luigia Luciano et al.|Institutional Research Information System University of Ferrara (University of Ferrara)|2010Cited by 1